http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3600418-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68c213ba9952360f439567152e047b18 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate | 2018-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_398f12df0a47c6da72f4e54fc2d8171f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_787569d0fee757508013923e3b14cdba |
publicationDate | 2020-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-3600418-A1 |
titleOfInvention | Low-density lipoprotein receptor related protein 5 inhibition suppresses tumor formation |
abstract | The present invention relates to the discovery that inhibition of the interaction between Dickkopf 2 (DKK2) and Low-Density Lipoprotein (LDL) Receptor Related Protein 5 (LRP5) and/or inhibition of LRP5 suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of an inhibiting agent that blocks the interaction between DKK2 and LRP5, methods of treating cancer by administering to a patient an effective amount of a LRP5 depleting agent, methods for providing anti-tumor immunity in a subject, and methods of stimulating a NK and T cell mediated immune response to a cell population or a tissue in a subject. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer. |
priorityDate | 2017-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1066.